Breaking News: FDA Approves a Highly Sensitive Prostate Cancer Imaging Agent

What this means for patients: Today, the FDA approved another highly sensitive imaging compound specifically for prostate cancer called 18F-DCFPyL. This is the second such approval in less than six months; in December, the FDA approved 68Ga-PSMA-11 PET. These pioneering…